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Objective: Giant cell tumor of bone (GCT) is a primary, osteolytic, benign tumor of the bone. Surgery is
the commonly used treatment; however, recurrence remains a problem. Receptor activator of nuclear
factor kappa B (RANKL) is responsible for the formation of osteoclastic cells. Discovery of RANKL and its
human monoclonal antibody, denosumab, led to use of denosumab for treatment of GCT. The aim of this
study was to evaluate clinical and pathological results of treatment of GCT with denosumab and to assess
adverse effect proﬁle and recurrence rate.
Methods: Thirteen patients with 14 lesions were enrolled in the study. Mean age was 38.3 years. Patients
were given subcutaneous injections of denosumab (120 mg) every 4 weeks (with additional doses on
days 0, 8 and 15 in cycle 1 only) and were radiologically evaluated for tumor response. Pain and func-
tional status were measured using Visual Analog Score (VAS) and Musculoskeletal Tumor Society Score
(MSTS). Adverse effects were analyzed after each cycle.
Results: Participants were 5 men and 8 women. Mean follow-up was 17 months. One lesion was Cam-
panacci grade I, 8 were grade II, and 5 were grade III. Eight lesions were recurrent, and remaining were
primary lesions. After average of 9 cycles (range: 4e17 cycles), all tumors underwent radiological
regression. Ten lesions were removed surgically. More than 90% of giant cells were found to have
regressed in all pathological specimens. On last follow-up, average VAS was 1 and MSTS was 87%. Fatigue
and joint and muscle pain after injections was reported by 46% of patients, and mild hypocalcaemia was
seen in 1 patient.
Conclusion: Denosumab has been shown to be a successful drug in treatment of GCT. Denosumab can be
used as neoadjuvant for all recurrent lesions, grade II lesions with high surgical risk, grade III lesions, and
metastatic cases of GCT.
Level of evidence: Level IV, Therapeutic study
© 2016 Turkish Association of Orthopaedics and Traumatology. Publishing services by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Giant cell tumor (GCT) is an aggressive, benign bone tumor. GCT,
which was ﬁrst deﬁned by Cooper and Travers, can produce pul-
monary metastasis, albeit rarely (1e6%).1,2 GCT constitutes 5% of
primary bone tumors and 20% of benign bone tumors. Although
GCT settles in metaphyseal area of long bones, particularly distal
femur and proximal tibia, followed by distal radius and proximal
humerus in 85% of cases, it is also seen in axial skeleton (10%) and inDeveci).
ciation of Orthopaedics and
s and Traumatology. Publishing sesmall bones of hands and feet (5%). GCT is common in third and
fourth decades of life, and frequently emerges in women.3
Radiologically, GCT is lytic lesion without mineralization that
often extends to subchondral area and is located eccentrically in
metaphysoephyseal region. It has no sclerotic edge, but is separated
from normal bone with narrow transition zone. It leads to cortical
thinning, expansion, or cortex destruction, and soft tissue compo-
nents may be found in more aggressive lesions. Pathological ﬁnd-
ings of GCT consist of osteoclast-like giant cells and proliferating
mononuclear round stromal cells, which are responsible for
neoplasia.4 Although osteoclast-like giant cells control bonervices by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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pathology and ensure formation of giant cells.5
The classic treatment for GCT is surgery. Following aggressive
curettage and high-speed burring, use of chemical adjuvants such
as phenol, alcohol, hydrogen peroxide, and liquid nitrogen, as well
as defect ﬁlling with grafts or bone cement are among most
frequently used methods of treatment. Endoprosthetic recon-
struction may also be used for grade III tumors with serious cortical
destruction.6 Recurrence rate ranges between 5% and 56%,
depending on cement and chemical adjuvants used during sur-
gery.7 Recurrence still continues to be the major problem. In
recurrent lesions, in lesions with wide soft tissue component, and
in surgically difﬁcult localizations like sacrum, spine, pelvis, and
distal radius, methods such as embolization, radiotherapy, or
bisphosphonates may be used.8,9
In the 1990s, effects of receptor activator of nuclear factor kappa
B ligand (RANKL) and receptor activator of nuclear factor kappa B
(RANK), members of the tumor necrosis factor (TNF) family, on
formation of osteoclasts and bone resorption were demon-
strated.10,11 It was seen that RANKL expression in stromal cells
caused neoplasia and stimulated both formation of osteoclast-like
giant cells and bone resorption with activation of RANK.12,13
Recognition of RANKL in pathogenesis led to investigations of po-
tential curative effect of suppression of this molecule. The result
was a humanmonoclonal immunoglobulin G2 antibody for RANKL,
denosumab. It was initially shown to decrease bone resorption in
postmenopausal osteoporosis and metastatic bone lesions.14e16
Thomas et al reported successful clinical and radiological results
with 120 mg denosumab dose in recurrent or inoperable GCT in a
phase 2 study in 2010.17 Denosumab was licensed for use in unre-
sectable lesions and relapse tumors and in lesions for which
resection would cause serious morbidity by the United States Food
and Drug Administration in 2013 and the European Medicines
Agency in 2014.18
The purpose of the present study was to evaluate clinical and
pathological results of 120mg subcutaneous denosumab treatment
in patients with GCT and examine recurrence rate and adverse ef-
fect proﬁle.
Patients and methods
Thirteen patients who were diagnosed as having GCT of bone
between April 2011 and January 2015 in our clinic were included in
this prospective study, conducted with permission from the Min-
istry of Health. Patient demographic data, tumor localization, and
previous treatments were recorded. All patients were radiologically
classiﬁed using Campanacci classiﬁcation19 after plain radiogra-
phies, bone scan, and computerized tomography (CT) of the lesion
and thorax, and magnetic resonance imaging (MRI) of lesion. Grade
I GCT is latent tumor inwhich the cortex is intact and its borders are
clearly separated. Grade II GCT is an active tumor, whose borders
can be separated, but there is no sclerotic edge; thinning is present
with expansion in cortex. Grade III GCT is aggressive lesion that has
ambiguous borders. Cortical destruction and soft tissue compo-
nents are present. A closed-needle biopsy was performed on pa-
tients with primary tumors. Diagnoses were conﬁrmed by re-
evaluating parafﬁn-embedded blocks of recurrent lesions. One
pathologist experienced in musculoskeletal system pathology un-
dertook all pathological evaluations. Prior to drug use, calcium,
phosphorus, and parathyroid hormone levels were measured in all
patients. All measured levels were found to be normal.
All recurrent lesions, grade II lesions with high surgical risk,
metastatic lesions, and grade III lesions were included in this study.
Subcutaneous injections of denosumab (120 mg) were given every
4 weeks (with additional doses on days 0, 8 and 15 in cycle 1 only).Concomitantly, 1500mg calcium carbonateþ400 IU vitamin Dwere
given daily.17,20 The number of cycles was recorded. Adverse effect
proﬁle was examined after each dose.
Radiographs were used to evaluate lesion mineralization, septa
formation, ossiﬁcation of soft tissue component, and corticalization
in each cycle of treatment, and CT in third month and at the end of
treatment. Final status of lesion of patients who underwent surgery
was examined with MRI after treatment. Postoperative patients
were assessed in terms of recurrence using radiography, CT, and
MRI every 3 months in the ﬁrst year.
Curettage or resection material after treatment was classiﬁed
using a 2-grade staging system developed for this study according
to the tumor response. Grade 1 was grouped as ﬁbrous tissue,
inﬂammation, and a small amount of woven bone formation; Grade
2 was deﬁned as woven bone, precancellous bone, and cancellous
bone formation.
Pain relief was evaluated after treatment and at last follow-up.
Pain scores of all patients were assessed using visual analog scale
(VAS) ranging 0 to 10. Functional status was evaluated using
Musculoskeletal Tumor Society (MSTS) Score at last follow-up.21
Statistical analysis
Statistical analyses were performed using Statistical Package for
Social Sciences software version 16 (SPSS Inc., Chicago, IL, USA).
Average and standard deviation were calculated for quantitative
variables, and number of cases was calculated for categorical vari-
ables. Differences between pre- and post-treatment VAS scores
were analyzed using t-test. P value less than 0.05 was considered
signiﬁcant.
Results
Fourteen lesions in 13 patients (5 men, 8 women; mean age:
38.3 years [range: 26e51 years]) diagnosed as GCT of bone and
treated with denosumab were included in the study. Average
length of follow-up was 17 months (range: 10e30 months). One
patient had multifocal lesions in proximal and distal femur. One
lesionwas grade I (multifocal lesionwith recurrent grade 2 lesion in
distal femur), 8 were grade II, and 5 were grade III. Six lesions were
primary, whereas 8 were recurrent. Two patients with recurrent
lesions had lung metastasis; these patients had been under follow-
up for GCT for more than 10 years. Demographic data, tumor
localization, radiological grade, and previous treatments are shown
in Table 1.
Due to availability of denosumab in our country, 4 patients
received 1  120 mg (Xgeva; Amgen, CA, USA) and 9 patients had
2  60 mg (Prolia; Amgen, CA, USA). An average of 9 cycles (range:
4e17 cycles) were administered.
Ten lesions were surgically treated following denosumab
administration, and resection/curettage specimens obtained were
pathologically examined (Figs. 1 and 2). Pathological evaluation
revealed that giant cells had regressed >90% in all cases. In 4 pa-
tients, 90% ossiﬁcation of lytic area was seen radiologically with
regression of pain; 3 of these patients continued follow-up without
treatment and 1 continues to receive denosumab treatment for
lung metastases. It was observed that lung lesions were regressing
and remained stable (Fig. 3). For patients who underwent curet-
tage, physical and chemical adjuvants such as high-speed burring,
electrocauterization, phenol, alcohol, or hydrogen peroxide were
used. Surgical treatments, number of treatment cycles, and path-
ological evaluation status are presented in Table 2. No recurrence
has been observed in surgically-treated patients.
Average pre-treatment pain VAS of 7 (range: 3e10) was reduced
to average of 2 after third cycle, and then 1 (range: 0e3) at last
Table 1
Demographic data of the patients, tumor localization, Campanacci grade, and previous treatments.
Patient # Sex (M/F) Age (years) Tumor localization Campanacci grade Recurrent/Primary Previous treatment
1 F 26 L proximal ﬁbula Grade III Recurrent Proximal ﬁbula resection
2 M 33 L distal femur Grade II Recurrent 2 times C/C
Fixation of pathological fracture
Lung metastases
3 F 36 Sacrum Grade II Primary
4a F 31 R distal femur Distal femur grade I Distal femur recurrent Distal femur C/C
R proximal femur Proximal femur grade II Proximal femur primary
5 M 36 R distal femur Grade II Primary
6 F 48 L proximal ﬁbula Grade III Primary
7 F 51 R proximal tibia Grade II Primary
8 M 37 R proximal humerus Grade III Recurrent 3 times C/C
9 F 35 L distal radius Grade III Recurrent C/G
10 F 39 R distal femur Grade II Recurrent 2 times C/C
11 M 49 R distal femur Grade II Recurrent C/G
Lung metastases
12 M 50 R distal radius Grade III Recurrent C/G
13 F 27 L proximal tibia Grade II Primary
C/C: Curettage-cementation; C/G: Curettage-grafting; L: Left; R: Right.
a Multifocal lesion.
Fig. 1. 26-year-old female who underwent proximal ﬁbula resection for giant cell tumor has recurrence in soft tissue. (a) Anteroposterior and (b) lateral radiographs show poorly
ossiﬁed lesion in soft tissue (arrow), which showed high degree of ossiﬁcation (arrow) after denosumab (c). Intraoperative view of resected lesion (d). 100 magniﬁcation with
hematoxilen-eosin stain shows 100% regression of the giant cells (arrow) (e) before denasumab (f) after denasumab.
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While assessing adverse effects, 6 patients (46%) reported fatigue,
muscle and joint pain for a few days after the injections, and 1
patient had mild hypocalcaemia. No patients were found to have
avascular necrosis of jaw, secondary infection, or other serious
adverse effect.
When the planned and performed surgeries before and after
denosumab were evaluated, no further surgical treatment applied
in 1 proximal ﬁbula lesion that were planned for resection and 3
recurrent distal femur lesions planed to have re-curettage andcementing. In the 10 patients who were surgically treated, the
planned surgery did not change.
Discussion
Treatment of GCT has continued for the last 30 years with no
perceptible change. Traditional treatments for grade I and II lesions
include aggressive curettage and high-speed burring, followed by
treatments with local adjuvants and defect-ﬁlling with graft or
bone cement.6 Use of methyl methacrylate has advantages due to
Fig. 2. 37-year-old man with giant cell tumor of proximal humerus previously treated with curettage and cementation. Anteroposterior radiograph (a) and computed tomography
(b) before treatment (arrows show lytic areas) and (d,e) after treatment (arrows show ossiﬁcation of lytic areas and soft tissue component). (e) Resection material and (f) post-
operative anteroposterior radiograph.
Fig. 3. Computed tomography images show regression of lung metastases. Arrows show (a) lesion before treatment and (b) after treatment.
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has led to less recurrence.22 Although local recurrence rates are
reported to decrease with use of chemical adjuvants, it is still up to
56%.7,23 In difﬁcult localizations such as sacrum and distal radius,recurrence rate within soft tissue is quite high. For these lesions,
embolization, radiotherapy, and use of interferon alfa and
bisphosphonates such as zoledronic acid are also
recommended.8,9,24e26
Table 2
Treatment after denosumab treatment and pathological grade.
Patient # Treatment Number
of cycles
Pathologic
evaluation
1 Resection of soft
tissue recurrence
12 Grade II
2 Follow-up without surgery 17
3 C/G 4 Grade II
4 Follow-up distal femur
C/G and IF proximal femur
8 Grade I
5 C/C 8 Grade I
6 Follow-up without surgery 10
7 C/C 8 Grade I
8 Resection and endoprosthetic
reconstruction
8 Grade II
9 Resection and reconstruction
with vascularized ﬁbula
8 Grade II
10 Follow-up 10
11 Resection and endoprosthetic
reconstruction
8 Grade I
12 C/C 8 Grade II
13 C/C 8 Grade I
C/C: Curettage-cementation; C/G: Curettage-grafting; IF: Internal ﬁxation.
Fig. 4. Fibro-osseous curettage specimen after denosumab treatment.
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years has identiﬁed RANKL in stromal cells, and the activity of this
molecule in cytogenesis of giant cells similar to osteoclasts through
osteoprotegerin, has made RANKL the real target of treatment.27
The ﬁrst phase 2 study, conducted by Thomas et al in 2010,
included a total of 37 patients from 8 centers with recurrent or
unresectable tumors. After loading on days 0, 8, and 15, a monthly
dose of 120 mg denosumab showed 86% good tumor response
histologically and radiologically.17 Another multi-center study in
2013 reported 41% complete and partial response, and 58% stable
disease after 7e20 doses of denosumab in group that could not be
resected surgically, and 58% complete and partial response and 41%
stable disease was achieved in group that was planned to undergo
surgery.20 Present study showed 100% radiological and pathological
response.
In this study, most frequently encountered adverse effects were
constitutional symptoms such as pain in extremities and back,
headache, fatigue, and mild hypocalcemia. Thomas et al reported
that 1 patient developed secondary bone sarcoma and another
patient developed mandibular osteonecrosis.17 Chawla et al re-
ported 84% of patients encountered arthralgia, headache, nausea,
fatigue, and back and extremity pain. Three patients were reported
to have mandibular osteonecrosis, and hypocalcemia was found in
15% of patients. Three patients had new primary malignant lesions;
however, only 1 of these was considered secondary malignant
transformation.20 Malignant transformation rate of GCT has been
reported to be 1%.18 Malignant degeneration may be caused by
dedifferentiation of tumor or secondary to previous radiotherapy
(50% of cases).28 Wojcik et al compared pathology samples of 9
patients treated with denosumabwith samples of 9 patients of GCT
with malignant transformation. In all patients, giant cells had been
eradicated. It was also noted that increase in cellularity and accu-
mulation of atypical and immature bone detected in patients in
early stages of denosumab treatment might be mistaken for pri-
mary bone sarcoma. In GCT, it has been documented that less atypia
and mitotic activity is seen and inﬁltrative growth pattern does not
exist, which is dissimilar to novo and secondary sarcomas. Patients
who receive longer-duration denosumab treatment have shown
decrease in cellularity and maturation in bone.29 It should be kept
in mind that less-experienced pathologists might evaluate such
changes in favor of bone sarcomas. Aponte-Tineo et al reported that
malignant transformation was encountered after denosumab in
recurring GCTs.30Although denosumab use in treatment of GCT causes fast
symptomatic and radiological recovery, is easy to use, and has a
good adverse effect proﬁle, there are still questions to be answered.
The ﬁrst is with regard to cytotoxic effect of denosumab on stromal
cells. In a study conducted by Lau et al, zoledronic acid was
compared with denosumab in terms of cytotoxicity on stromal
cells. Zoledronic acid was found to have caused decreased growth
of stromal cells and dose-dependent apoptosis, whereas denosu-
mab had minimal inhibitory effect without causing apoptosis.31
This raises the question as to whether denosumab is only effec-
tive while it is being used; there are no studies about length of
denosumab treatment on unresectable or recurrent lesions that are
followed-up without surgery. Furthermore, considering that RANK
and RANKL are found in many systems of the body, effects of long-
term inhibition on other organ systems are not yet known.
In studies that compared whether difference was achieved in
planned and performed surgery, it was evaluated that among 222
patients who used denosumab for an average of 15.3 months, 38%
underwent less morbid surgery with an 80% decrease in need for
hemipelvectomy and amputations, and 85% success in preservation
of joints. A 15% recurrence rate was reported during 13 months of
follow-up. Risk was found to be higher when bone grafting had
been performed and adjuvants had not been used.32 There is still no
consensus about use of denosumab after surgery in the literature.
Rutkowski et al. reported that 106 patients who did not have sur-
gery were symptom free and had stable sclerosis on follow-up after
an average of 22.5 doses of denosumab.32
Although ossiﬁcation of soft tissue component and lytic cortex,
as well as less bleeding are factors that facilitate surgery, curettage
of tough, ﬁbrous, and sclerotic tissue that forms after denosumab
treatment becomes quite difﬁcult (Fig. 4). It is also difﬁcult to
separate pathological and normal tissue during curettage. It should
be kept in mind that live cells may remain in developed bone
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equipment. Adjuvant treatments should not be forsaken.
The weaknesses of this study may be counted as the following:
limitation of the number of patients and heterogeneous distribu-
tion of cases. To evaluate medical treatment efﬁciency of this rare
primary bone tumor, multi-center studies with more homogenous
groups must be planned. Prospective design, description of a new
pathological classiﬁcation, and detailing personal surgical experi-
ence are very strong points of this study.Conclusion
Good clinical and radiological results can be achieved with
denosumab use in GCT, and it has a safe adverse effect proﬁle. We
recommend that it be used as a neoadjuvant treatment in all
recurrent patients, in grade II lesions with high surgical risk, met-
astatic lesions and grade III lesions.References
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